Novo Nordisk is involved in a clinical trial using the company’s GLP-1 analog diabetes drug Victoza to evaluate if the medicine can improve brain function and cognition in Alzheimer’s patients.
In August 1963, the Rev. Martin Luther King delivered his famous “I Have a Dream” speech that called for equality among all people, regardless of their ethnicity, as well as a vision for a better America for all. While the noble dreams that King outlined on that hot day in Washington, D.C. so many years ago have unfortunately not yet been fully realized, there are other kinds of dreams that may be closer to being achieved, particularly in the area of new medications for serious diseases.
Roche is expecting the U.S. Food and Drug Administration to approve the company’s SMA therapy risdiplam by May 24, 2020, and has suggested plans to undercut both Biogen and Novartis on price in order to make up for being third-to-market.
Biogen Inc. agreed to buy an early-stage experimental treatment from Pfizer Inc. to test in patients with Alzheimer’s and Parkinson’s disease.
Novartis aims to give away 100 doses of the company’s $2.1 million-per-patient Zolgensma for spinal muscular atrophy (SMA) in 2020 in a free-drug program that one patient group worried was a “health lottery” that could neglect some babies.
Biogen is discontinuing development of an experimental therapy for a rare brain disease after the treatment failed a mid-stage trial, the latest setback in attempts to develop a medicine for the disorder.
Dublin, Ireland-based Alkermes is acquiring Boston-based Rodin Therapeutics for $100 million up front and up to $850 million in milestone payments.
Researchers with Rockefeller University discovered something completely unexpected – the affected neurons in Parkinson’s disease may not be dead.
Roche’s bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift as the Swiss drugmaker’s drug risdiplam improved motor function of patients in a key study.
U.S. regulators halted a trial of Novartis’ Zolgensma treatment after an animal study raised safety concerns, in a setback for the drugmaker’s plan to expand the product’s use to older patients.
